Investments in Latin America’s healthtech sector surged by 37.6% in 2024, reaching $253.7 million, according to the HealthTech Recap 2024 report by Distrito and ABSS.
This marks a recovery after two years of declining investment, driven by a shift toward funding more mature startups with scalable business models. Despite fewer funding rounds—56 compared to 71 in 2023—the total investment increased significantly, reflecting larger ticket sizes for later-stage companies.
Series A and B rounds, while only 14% of all deals from 2014 to 2024, accounted for half of the total capital invested during that period. This trend underscores growing investor selectivity, prioritizing startups capable of delivering measurable results and scaling quickly.
Brazil emerged as a key player, hosting nearly two-thirds of the region’s healthtech startups and securing four of the five largest funding rounds in 2024.
Companies like Amigo ($33 million Series B), Mevo ($20 million Series B), and Beep ($17 million Series D) attracted substantial investments, highlighting their market readiness and potential for expansion. Together, these firms represented over a quarter of the region’s total funding for the year.
The report also noted rising use of artificial intelligence in healthtech, with AI-driven startups growing from 14% to 20% of the sector over two years.
However, early-stage startups still face funding challenges, capturing only 25% of total investment despite representing 85% of all deals between 2014 and 2024.
This growth signals increasing confidence in Latin America’s healthtech sector but also highlights barriers like limited early-stage funding and regulatory hurdles that need addressing for sustained progress.